Drug intelligence / Profile preview

carbamazepine + clonazepam + sertraline

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

This is a combination of three pharmaceutical drugs—carbamazepine, clonazepam, and sertraline—each with distinct mechanisms of action and clinical uses. - **Carbamazepine** is an anticonvulsant and analgesic used primarily to control seizures (especially in epilepsy), treat trigeminal neuralgia (a type of nerve pain), and manage symptoms of bipolar disorder. It acts mainly by inhibiting voltage-gated sodium channels in neuronal membranes, stabilizing hyperexcited nerve cells[1][7]. - **Clonazepam** is a benzodiazepine indicated for the treatment of panic disorder and certain types of seizure disorders. It enhances the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor, producing anxiolytic, anticonvulsant, muscle relaxant, and sedative effects[5]. - **Sertraline** is a selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat major depressive disorder, anxiety disorders including social anxiety disorder and panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), among others. Sertraline increases synaptic serotonin levels by inhibiting its reuptake into presynaptic neurons[4][6]. There are no known fixed-dose combination products containing all three agents; this listing refers to their concurrent use as individual medications.

02

Targets

SERT (Sodium-dependent serotonin transporter)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on carbamazepine + clonazepam + sertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on carbamazepine + clonazepam + sertraline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call